Travere, with its conditionally approved FILSPARI, is the only Tarpeyo alternative for US patients. Tarpeyo has delivered solid eGFR results over 2-years, and we expect more details in next week’s international symposium. Today, Travere published top-line data over 2-years that fails to match Tarpeyo. This is, of course, good news for Tarpeyo and in line with our expectations. Tarpeyo’s eGFR results are potentially disease-modifying. We expect Tarpeyo to secure unconditional approval, which can support the reimbursement process in the private insurance channel. Our Base cse is SEK 295 (Bull SEK 445 and Bear SEK 75).